IP Library Granted Patent US 7,932,253
Granted Patent B2
US 7,932,253 · App. 11/659,035 · Granted Apr 26, 2011

Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors

Assignee: MediGene AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,253
App. No.
11/659,035
Granted
Apr 26, 2011
Kind
B2
Abstract

N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-4-(6,9-difluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide is a CD80 antagonist, useful in the treatment of diseases which benefit from immuno-inhibition.

Claims (4)

1. N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-4-(6,9-difluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide or a salt thereof.

2. A compound as claimed in claim 1 in the form of the (R)-enantiomer.

3. A pharmaceutical or veterinary composition comprising N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-4-(6,9-difluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide or a salt thereof together with a pharmaceutically or veterinarily acceptable excipient or carrier.

4. A pharmaceutical or veterinary composition according to claim 3 comprising N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-4-(6,9-difluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide or a salt thereof in an amount to treat conditions which benefit from immunomodulation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2011
From: MEDIGENE LIMITED
To: MEDIGENE AG
Reel/Frame 025938/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2008
From: MATTHEWS, IAN RICHARD
To: MEDIGENE LIMITED
Reel/Frame 021739/0530 →
Continuity (1)
Related Publication 20090062289A1 · Mar 5, 2009